ArticleCell death & disease2026
TIGAR maintains intestinal epithelial regeneration by stabilizing HMGCL and promoting β-catenin β-hydroxybutyrylation in burn-induced sepsis.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Burn-induced sepsis triggers profound intestinal injury, contributing to systemic inflammation and organ damage. Beta-hydroxybutyrate (BHB), a major ketone body, acts as a key regulator of intestinal epithelial regeneration. Its metabolic dysregulation has been implicated in impaired cell proliferation and the maintenance of intestinal stem cells (ISCs). However, the dynamic regulatory mechanisms underlying BHB fluctuation during burn sepsis-induced intestinal injury remain elusive. In this study, we demonstrate that TIGAR expression is markedly reduced in small intestinal crypts of burn sepsis mice. TIGAR deficiency substantially diminishes BHB production and compromises cell proliferation and ISC self-renewal capacity. Mechanistically, the 1-131 domain of TIGAR orchestrate dual functionality: it acts as a mitochondrial targeting signal to direct TIGAR localization and competitively binds the ketogenic enzyme HMGCL, thereby inhibiting its interaction with the E3 ubiquitin ligase Park2. This spatial interference blocks Park2-mediated K48-linked ubiquitination and proteasomal degradation of HMGCL, and stabilizing HMGCL to enhance BHB synthesis. Elevated BHB induces β-hydroxybutyrylation at lysine 335 of β-catenin, which facilitates β-catenin nuclear translocation and strengthens its interaction with TCF4, therefore driving cell proliferation and ISC self-renewal, ultimately maintaining intestinal epithelial regeneration. Collectively, this study identifies a novel role of TIGAR in maintaining intestinal barrier regeneration by promoting ketone body production. This previously unexplored mechanism of TIGAR may serve as a critical compensation for the treatment of burn-related gut barrier dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.